Weight Loss
Let us support you on your journey to a healthier, more vibrant you.
Tirzepatide
Tirzepatide is another popular weight loss treatment within the same class as Semaglutide. Like Semaglutide, Tirzepatide is also an incretin mimetic. However, Tirzepatide works differently by acting on GIP and GLP-1 receptors. Semaglutide only works on the GLP-1 receptor. Both drugs are used for treating type-2 diabetes. As a dual-acting GIP and GLP-1, Tirzepatide lowers fasting and postprandial glucose concentrations. In addition, Tirzepatide decreases food intake, reduces body weight, improves the health of patients, and overall enhances their quality of life.
Retatrutide
Retatrutide is an experimental drug developed by Eli Lilly that works as a triple hormone receptor agonist, targeting GLP‑1, GIP, and glucagon receptors. This unique mechanism helps reduce appetite, regulate blood sugar, and boost metabolism. In clinical trials, retatrutide has delivered impressive results, with participants losing up to 24% of their body weight in 48 weeks, which exceeds the effectiveness of current medications like Ozempic (semaglutide) and Mounjaro (tirzepatide). It has also shown significant benefits in reducing liver fat and improving cardiovascular risk markers, making it a promising option for obesity and related metabolic disorders.
However, retatrutide is still in Phase 3 trials and has not yet received FDA approval, with anticipated availability around 2027–2028. The most common side effects are gastrointestinal issues such as nausea, diarrhea, and constipation, while rare cases of very rapid weight loss have prompted safety reviews. If long-term studies confirm its safety and effectiveness, retatrutide could become one of the most powerful treatments for obesity, type 2 diabetes, and associated health risks.
Trusted Care. Proven Results.
Join patients choosing a smarter, proactive approach to modern medicine.
Or call: 201-983-2582